Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9H074
UPID:
PAIP1_HUMAN
Alternative names:
-
Alternative UPACC:
Q9H074; A6NKV8; O60455; Q96B61; Q9BS63
Background:
Polyadenylate-binding protein-interacting protein 1 plays a pivotal role in the regulation of translation initiation of poly(A)-containing mRNAs. It enhances translation by acting on PABPC1 and competes with PAIP2 for PABPC1 binding. Its interaction with EIF4A and PABPC1 may enhance mRNA termini contacts, and it's involved in mRNA turnover. Additionally, it interacts with SARS-CoV NSP3 protein, aiding in viral protein synthesis.
Therapeutic significance:
Understanding the role of Polyadenylate-binding protein-interacting protein 1 could open doors to potential therapeutic strategies.